Literature DB >> 34029379

Tumour brain: Pretreatment cognitive and affective disorders caused by peripheral cancers.

Myrthe Mampay1, Melanie S Flint1, Graham K Sheridan2.   

Abstract

People that develop extracranial cancers often display co-morbid neurological disorders, such as anxiety, depression and cognitive impairment, even before commencement of chemotherapy. This suggests bidirectional crosstalk between non-CNS tumours and the brain, which can regulate peripheral tumour growth. However, the reciprocal neurological effects of tumour progression on brain homeostasis are not well understood. Here, we review brain regions involved in regulating peripheral tumour development and how they, in turn, are adversely affected by advancing tumour burden. Tumour-induced activation of the immune system, blood-brain barrier breakdown and chronic neuroinflammation can lead to circadian rhythm dysfunction, sleep disturbances, aberrant glucocorticoid production, decreased hippocampal neurogenesis and dysregulation of neural network activity, resulting in depression and memory impairments. Given that cancer-related cognitive impairment diminishes patient quality of life, reduces adherence to chemotherapy and worsens cancer prognosis, it is essential that more research is focused at understanding how peripheral tumours affect brain homeostasis.
© 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

Entities:  

Keywords:  blood-brain barrier; cancer-related cognitive impairment; circadian rhythms; depression; hypothalamic-pituitary-adrenal axis; inflammation; stress; tumour brain

Year:  2021        PMID: 34029379     DOI: 10.1111/bph.15571

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  7 in total

1.  Association of markers of tumor aggressivity and cognition in women with breast cancer before adjuvant treatment: The Thinking and Living with Cancer Study.

Authors:  Jeanne S Mandelblatt; Tim A Ahles; James C Root; Xingtao Zhou; Jaeil Ahn; Brent J Small; Wanting Zhai; Traci Bethea; Judith E Carroll; Harvey Jay Cohen; Asma Dilawari; Martine Extermann; Deena Graham; Claudine Isaacs; Paul B Jacobsen; Heather Jim; Brenna C McDonald; Zev M Nakamura; Sunita K Patel; Kelly Rentscher; Andrew J Saykin; Kathleen Van Dyk
Journal:  Breast Cancer Res Treat       Date:  2022-05-19       Impact factor: 4.624

2.  Pre-Surgery Demographic, Clinical, and Symptom Characteristics Associated with Different Self-Reported Cognitive Processes in Patients with Breast Cancer.

Authors:  Yu-Yin Allemann-Su; Marcus Vetter; Helen Koechlin; Steven M Paul; Bruce A Cooper; Kate Oppegaard; Michelle Melisko; Jon D Levine; Yvette Conley; Christine Miaskowski; Maria C Katapodi
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

3.  Cancer as a tool for preclinical psychoneuroimmunology.

Authors:  Jeremy C Borniger
Journal:  Brain Behav Immun Health       Date:  2021-09-21

4.  Circadian Gene cry Controls Tumorigenesis through Modulation of Myc Accumulation in Glioblastoma Cells.

Authors:  Patricia Jarabo; Carmen de Pablo; Amanda González-Blanco; Sergio Casas-Tintó
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

5.  Longitudinal Association of Universal Screening and Treatment for Major Depressive Disorder with Survival in Cancer Patients.

Authors:  Yung-Chieh Yen; Chin-Yu Huang; Hsue-Wei Chan; You-Yu Wang; Te-Chang Changchien; Deng-Wu Wang; Po-Chun Lin; Ting-Ting Chang; Yu-Wen Chiu
Journal:  J Pers Med       Date:  2022-07-26

6.  The alterations in event-related potential responses to pain empathy in breast cancer survivors treated with chemotherapy.

Authors:  Wen Li; Yue Lv; Xu Duan; Guo Cheng; Senbang Yao; Sheng Yu; Lingxue Tang; Huaidong Cheng
Journal:  Front Psychol       Date:  2022-09-23

Review 7.  A multidisciplinary perspective on the complex interactions between sleep, circadian, and metabolic disruption in cancer patients.

Authors:  Lasse D Jensen; Delmy Oliva; Bengt-Åke Andersson; Freddi Lewin
Journal:  Cancer Metastasis Rev       Date:  2021-12-27       Impact factor: 9.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.